免疫检查点抑制剂的免疫相关严重不良事件:系统性审查和网络元分析
Clara Oliveira1,2, Beatrice Mainoli1,2,3, Gonçalo S Duarte1,2,4
1Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisbon, Portugal.
免疫检查点抑制剂 (ICI) 的安全性各不相同. 阿特佐利祖马布显示出最好的安全性概况,而伊皮利穆马布在癌症患者中,免疫相关的严重不良事件 (irSAE) 的发生率最高.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫检查点抑制剂 (ICI) 已经改变了癌症治疗,但存在安全问题.
- 评估与ICI相关的免疫相关严重不良事件 (irSAE) 的比较安全性和绝对率对于临床决策至关重要.
结论:
- 每个ICI都有一个独特的安全概况,与特定的IRSAE与特定的药物相关.
- 临床医生在选择和管理癌症患者的ICI时应该考虑这些独特的安全性.
更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
相关概念视频
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Cell-mediated Immune Responses
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
